Skip to content
2000
Volume 4, Issue 4
  • ISSN: 1573-3947
  • E-ISSN: 1875-6301

Abstract

Colorectal cancer (CRC) is a serious complication of inflammatory bowel disease (IBD). Although conclusive evidence is still missing, epidemiological and preliminary clinical work strongly suggests that mesalazine may have chemopreventive properties against IBD-related CRC. Therefore, in recent years, several experimental studies have been conducted to dissect the mechanism(s) by which mesalazine interferes with CRC cell growth and survival. This review summarizes the current information on the molecular pathways that are regulated by mesalazine in CRC.

© Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cctr/10.2174/157339408786413326
2008-11-01
2025-09-24

  • From This Site

    /content/journals/cctr/10.2174/157339408786413326
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/content/journals/cctr/10.2174/157339408786413326
Loading

  • Article Type:     Research Article
Keyword(s): Colorectal cancer (CRC); EGFR; inflammatory bowel disease (IBD); mesalazine; molecular pathways

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test